Lennox–Gastaut Syndrome (LGS) Market Growth Analysis
Lennox–Gastaut Syndrome (LGS) is a severe pediatric epilepsy syndrome characterized by the presence of multiple pharmaco-resistant seizure types, including tonic, atypical absences, and tonic or atonic drop attacks, and the presence of electroencephalographic abnormalities.
As per the Delveinsight, in 2017, the market size of Lennox–Gastaut Syndrome (LGS) in the 7MM was 136.6 Million. The total prevalent population of Lennox–Gastaut Syndrome (LGS) in the 7 MM was 111,798 in 2017. The prevalent population of LGS in the United States was 47,256.
Some of the key companies in the Lennox–Gastaut Syndrome (LGS) Market include Eisai, Zogenix, Takeda, Ovid, and many others.
Source: Lennox–Gastaut Syndrome (LGS) Market Growth Analysis